TICKERNERD
Menu
CICIHealthcare · Healthcare Plans

CI Stock Forecast: The Cigna Group Price Predictions for 2026-2027

Last close, 21 Aug 2026
$277
+1.12% on the day

The 24 Wall Street analysts covering The Cigna Group hold a median 12-month price target of $343 — +23.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 70 of 100 as at 22 Aug 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$73.3B
Ticker Nerd rank
70 / 100
Median analyst target
$343
Analysts covering
24
Total return, dividends reinvested
1W
−1.8%
1M
−4.5%
YTD
+2.0%
1Y
−5.8%
From 52W high
−9.3%
From 52W low
+15.5%
$240
$306
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores The Cigna Group on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
70 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
98
Value
97
Growth
81
Issuance
71
Revisions
69
Quality
47
Momentum
44
Accruals
38
Size
4

Volatility (98): The share price has been relatively steady.

Accruals (38): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (4): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$250$300$350$400Oct 25Jan 26Apr 26Jul 26CIHigh $400Median $343Low $290

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says24 analysts
19 Buy5 Hold0 Sell
Low $290Median $343High $400

The green dot is the last close — the median target sits +23.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
4 Aug 2026JefferiesDowngradeHold$336 → $307
3 Aug 2026Raymond JamesDowngradeOutperform$350 → $320
31 July 2026BarclaysMaintainsEqual-Weight$304 → $310
31 July 2026GuggenheimMaintainsBuy$338 → $361
31 July 2026Wells FargoMaintainsEqual-Weight$305 → $307
9 July 2026BernsteinMaintainsOutperform—
9 July 2026BernsteinMaintainsOutperform$371 → $381
8 June 2026MizuhoMaintainsOutperform—
26 May 2026BarclaysDowngradeEqual-Weight—
22 May 2026UBSMaintainsBuy—
20 May 2026Deutsche BankDowngradeHold—
20 May 2026Morgan StanleyMaintainsOverweight—
5 May 2026BernsteinMaintainsOutperform—
4 May 2026GuggenheimMaintainsBuy—
1 May 2026BarclaysMaintainsOverweight—
1 May 2026Cantor FitzgeraldMaintainsOverweight—
1 May 2026RBC CapitalMaintainsOutperform—
1 May 2026Wells FargoMaintainsEqual-Weight—
20 Apr 2026JefferiesMaintainsBuy—
12 Mar 2026BernsteinUpgradeOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+0.4%
Analysts raising
19
Analysts cutting
1
Fundamentals

The Cigna Group (CI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
11.5×

Cheaper than 56% of US stocks

Price / sales
0.3×

Cheaper than 91% of US stocks

Price / book
1.7×

Cheaper than 52% of US stocks

EV / EBITDA
7.7×

Cheaper than 47% of US stocks

Growth & margins
Revenue growth (YoY)
6.7%

Higher than 43% of US stocks

Earnings growth (YoY)
8.4%

Higher than 46% of US stocks

Gross margin
8.8%

Higher than 9% of US stocks

Operating margin
4.0%

Higher than 52% of US stocks

Net margin
2.3%

Higher than 53% of US stocks

Returns & dividend
Return on equity
16.8%

Higher than 77% of US stocks

Return on assets
4.5%

Higher than 73% of US stocks

Dividend yield
2.2%

Higher than 51% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealthcare Plans
CompanyMarket capTKN rank
CIThe Cigna Group$73.3B
70
ELVElevance Health, Inc.$89.0B
66
HUMHumana, Inc.$45.6B
45
CVSCVS Health Corp.$118.1B
87
CNCCentene Corp.$32.0B
93
UNHUnitedHealth Group, Inc.$353.4B
75
MOHMolina Healthcare, Inc.$10.3B
32

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own The Cigna Group — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CI news & analysis

Here's Why Investors Should Stay Neutral on Cigna Stock for Now

Zacks Investment Research · 19 Aug 2026neutral

Zacks Investment Research advises investors to remain neutral on Cigna (CI) stock, noting that the company's growth and shareholder returns are being weighed against rising costs, medical expenses, and debt.

Why it matters — A CI watcher would care because the report highlights the balance between Cigna's growth and shareholder returns versus the pressures of rising costs, medical expenses, and debt.

Cigna: I'm Buying What Others Are Ignoring

Seeking Alpha · 17 Aug 2026positive

A Seeking Alpha article reiterates a bullish stance on Cigna, citing double-digit adjusted EPS growth, shares trading 28% below fair value, and growth drivers in the Accredo and AI-powered Pharmacy Forward platforms. It also highlights Cigna's A- credit rating, strong free cash flow, and a growing dividend with low payout ratios, with revenue and margin expansion expected through 2028.

Why it matters — A Cigna watcher would note this as a positive analyst assessment highlighting the company's growth platforms, financial strength, and valuation as supportive of its outlook.

Why Cigna (CI) is a Top Value Stock for the Long-Term

Zacks Investment Research · 12 Aug 2026positive

Zacks Investment Research highlights Cigna as a top value stock for the long term, using its Style Scores system to rank stocks by investing style. The piece points to Cigna as among the top-rated stocks based on this methodology.

Why it matters — A favorable value-stock designation from Zacks could signal positive long-term prospects that CI shareholders may find reassuring.

Here's Why Cigna (CI) is a Strong Growth Stock

Zacks Investment Research · 7 Aug 2026positive

Zacks Investment Research, using its Style Scores feature, identifies Cigna (CI) as a strong growth stock. The piece highlights the Zacks Premium research tool as a way for investors to find strong stocks.

Why it matters — A favorable growth-stock designation from Zacks signals that Cigna stands out positively in the research firm's screening framework, which CI watchers may note.

Cigna's Valuation Gap Still Stands Out

Seeking Alpha · 31 July 2026positive

Seeking Alpha reaffirmed a Buy rating on Cigna, noting its valuation remains deeply discounted despite steady earnings growth, raised 2026 adjusted EPS guidance to at least $30.45, and ongoing capital returns including buybacks and a $1.56 per share dividend.

Why it matters — CI watchers would note the raised EPS guidance and continued capital return program as signs of financial momentum and shareholder value focus.

FAQ

Frequently asked questions about CI stock

What is the CI stock price forecast for 2026-2027?

The 24 Wall Street analysts covering The Cigna Group have a median 12-month price target of $343, with estimates ranging from $290 to $400. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CI stock a buy right now?

Of the 24 analysts covering The Cigna Group, 19 rate it a Buy, 5 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks The Cigna Group 70 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CI?

As at 22 Aug 2026, The Cigna Group ranks 70 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (98 of 100).

Will CI stock go up?

No one can know that. What the data says: the median 12-month target from 24 analysts implies +23.6% from the last close, and Ticker Nerd's factor model ranks The Cigna Group 70 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CI stock forecast for 2030?

No analyst covering The Cigna Group publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $290 to $400 over the next 12 months.

How has CI stock performed over the past year?

The Cigna Group returned -5.8% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does The Cigna Group do?

The Cigna Group is a global health company that provides a broad range of health services and solutions to individuals, employers, health plans, and government organizations. Through its Evernorth Health Services segment, the company delivers pharmacy benefit management, home delivery and specialty pharmacy services, specialty drug distribution, and care delivery and management solutions that support cost-effective and clinically focused care.

What is the latest news on CI?

The most recent item we track (Zacks Investment Research, 19 Aug 2026): "Here's Why Investors Should Stay Neutral on Cigna Stock for Now". Zacks Investment Research advises investors to remain neutral on Cigna (CI) stock, noting that the company's growth and shareholder returns are being weighed against rising costs, medical expenses, and debt.

Company

About The Cigna Group.

The Cigna Group is a global health company that provides a broad range of health services and solutions to individuals, employers, health plans, and government organizations. Through its Evernorth Health Services segment, the company delivers pharmacy benefit management, home delivery and specialty pharmacy services, specialty drug distribution, and care delivery and management solutions that support cost-effective and clinically focused care. Its Cigna Healthcare segment offers comprehensive medical coverage and coordinated health solutions across U.S. commercial, government, and international markets, serving employers and other institutional clients as well as individuals. The Other Operations and Corporate segments encompass remaining business activities and centralized functions, including certain ongoing and exited businesses, corporate overhead, and shared services. Headquartered in Bloomfield, Connecticut, and founded in 1792, The Cigna Group plays a significant role in the managed health care and health services sector by integrating benefits, clinical programs, and pharmacy capabilities to support access to healthcare and coordinated patient care.

CEO Mr. Brian Case Evanko C.F.A. · 65,669 employees · United States · https://www.thecignagroup.com